Table 1 Summary of inclusion criteria for the studied RT locations with clinically oriented dose prescription and planning objectives for the PTV
From: The impact of flattening-filter-free beam technology on 3D conformal RT
Tumor site | Study criteria | Prescription [Gy] | Dose/fx [Gy] | PTV constraints | n | Comments |
|---|---|---|---|---|---|---|
Breast | Whole Breast, without supraclavicular LN | 50.0 | 2.0 | V95%>90%, D2%<107% | 13 | |
Lung | Mediastinum ± hilus, without supraclavicular LN | 50.0 | 2.0 | V95%>95%, D2%<107% | 7 | |
Neurocranium | Whole brain | 30.0 | 3.0 | V95%>99%, D2%<107% | 11 | |
Bone Metastasis | Spine locations with max. 4 vertebrae | 37.5 | 2.5 | V95%>99%, D2%<107% | 10 | C=3, TH=5, L=2 |
Prostate | Prostatic bed/ prostate | 66.0(Prostatic bed) | 2.0 | V95%>99%, D2%<107% | 11 |